Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials

BACKGROUND: Pirfenidone is an oral antifibrotic agent that has been shown to reduce the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an integrated analysis of safety data from five clinical trials evaluating pirfenidone in patients with IPF. METHODS: Al...

Descripción completa

Detalles Bibliográficos
Autores principales: Lancaster, Lisa, Albera, Carlo, Bradford, Williamson Z, Costabel, Ulrich, du Bois, Roland M, Fagan, Elizabeth A, Fishman, Robert S, Glaspole, Ian, Glassberg, Marilyn K, King, Talmadge E, Lederer, David J, Lin, Zhengning, Nathan, Steven D, Pereira, Carlos A, Swigris, Jeffrey J, Valeyre, Dominique, Noble, Paul W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Interstitial Lung Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716177/
https://www.ncbi.nlm.nih.gov/pubmed/26835133
http://dx.doi.org/10.1136/bmjresp-2015-000105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716177/
https://www.ncbi.nlm.nih.gov/pubmed/26835133
http://dx.doi.org/10.1136/bmjresp-2015-000105

Ejemplares similares